Correction to: Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma (Cell Cycle, 13, 4, (652-665), 10.4161/cc.27546);Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma

Cell Cycle

Volumn 13, Issue 4, 2014, Pages 652-665

  Di Marzo, Domenico ^a   Forte, Iris Maria ^a   Indovina, Paola ^b,c   Di Gennaro, Elena ^a   Rizzo, Valeria ^b   Giorgi, Francesca ^b   Mattioli, Eliseo ^b,d   Iannuzzi, Carmelina Antonella ^a,b   Budillon, Alfredo ^a   Giordano, Antonio ^a,b,c   Pentimalli, Francesca ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c Temple University   (United States)

^d NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Apoptosis; Mesothelioma; Nutlin 3; p21; RITA; TP53 mutations

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; CISPLATIN; MUTANT PROTEIN; NUTLIN 3; PROTEIN P21; PROTEIN P53; REACTIVATION OF P53 AND INDUCTION OF TUMOR CELL APOPTOSIS; UNCLASSIFIED DRUG; FURAN DERIVATIVE; IMIDAZOLE DERIVATIVE; NSC 652287; PIPERAZINE DERIVATIVE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIPHASIC MESOTHELIAL CELL; CANCER CELL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG TARGETING; EPITHELIOID MESOTHELIAL CELL; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PLEURA MESOTHELIOMA; POINT MUTATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REACTIVATION OF P53 AND INDUCTION OF TUMOR CELL APOPTOSIS APPROACH; SARCOMATOID MESOTHELIAL CELL; TUMOR GROWTH; WILD TYPE; CELL CYCLE; CELL SURVIVAL; DRUG EFFECTS; LUNG TUMOR; MESOTHELIOMA; METABOLISM; MUTATION; PATHOLOGY; PLEURA TUMOR; TUMOR CELL LINE; XENOGRAFT;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG SYNERGISM; FURANS; HETEROGRAFTS; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; MESOTHELIOMA; MUTATION; PIPERAZINES; PLEURAL NEOPLASMS; RHO GTP-BINDING PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84896842759     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.1080/15384101.2020.1853405     Document Type: Erratum

References (61)

1. William D. Travis, Elisabeth Brambilla, H. Konrad Müller-Hermelink, Curtis C. Harris, eds. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France: IARCPress International Agency for Research on Cancer (IARC) 2004.
2. LaDou J, Castleman B, Frank A, Gochfeld M, Greenberg M, Huff J, Joshi TK, Landrigan PJ, Lemen R, Myers J, et al. The case for a global ban on asbestos. Environ Health Perspect 2010; 118:897-901; PMID:20601329; http://dx.doi.org/10. 1289/ehp.1002285
3. Stayner L, Welch LS, Lemen R. The worldwide pandemic of asbestos-related diseases. Annu Rev Public Health 2013; 34:205-16; PMID:23297667; http://dx.doi.org/10.1146/annurev-publhealth-031811-124704
4. Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol 2009; 27:2081-90; PMID:19255316; http://dx.doi.org/10.1200/JCO. 2008.19.8523
5. Bullock AN, Fersht AR. Rescuing the function of mutant p53. Nat Rev Cancer 2001; 1:68-76; PMID:11900253; http://dx.doi.org/10.1038/35094077
6. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408:307-10; PMID:11099028; http://dx.doi.org/10.1038/35042675
7. Metcalf RA, Welsh JA, Bennett WP, Seddon MB, Lehman TA, Pelin K, Linnainmaa K, Tammilehto L, Mattson K, Gerwin BI, et al. p53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res 1992; 52:2610-5; PMID:1568228
8. Mor O, Yaron P, Huszar M, Yellin A, Jakobovitz O, Brok-Simoni F, Rechavi G, Reichert N. Absence of p53 mutations in malignant mesotheliomas. Am J Respir Cell Mol Biol 1997; 16:9-13; PMID:8998073; http://dx.doi.org/10.1165/ajrcmb.16. 1.8998073
9. Cheng JQ, Jhanwar SC, Klein WM, Bell DW, Lee WC, Altomare DA, Nobori T, Olopade OI, Buckler AJ, Testa JR. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994; 54:5547-51; PMID:7923195
10. Prins JB, Williamson KA, Kamp MM, Van Hezik EJ, Van der Kwast TH, Hagemeijer A, Versnel MA. The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma. Int J Cancer 1998; 75:649-53; PMID:9466670; http://dx.doi.org/10.1002/(SICI)1097-0215(19980209)75: 4〈649: :AIDIJC25〉3.0.CO;2-2
11. Lecomte C, Andujar P, Renier A, Kheuang L, Abramowski V, Mellottee L, Fleury-Feith J, Zucman-Rossi J, Giovannini M, Jaurand MC. Similar tumor suppressor gene alteration profiles in asbestos-induced murine and human mesothelioma. Cell Cycle 2005; 4:1862-9; PMID:16319530; http://dx.doi.org/10. 4161/cc.4.12.2300
12. Yang CT, You L, Uematsu K, Yeh CC, McCormick F, Jablons DM. p14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53. Cancer Res 2001; 61:5959-63; PMID:11507034
13. Yang CT, You L, Yeh CC, Chang JW, Zhang F, McCormick F, Jablons DM. Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells. J Natl Cancer Inst 2000; 92:636-41; PMID:10772681; http://dx.doi.org/10.1093/jnci/92.8. 636
14. Hopkins-Donaldson S, Belyanskaya LL, Simões-Wüst AP, Sigrist B, Kurtz S, Zangemeister-Wittke U, Stahel R. p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma. Neoplasia 2006; 8:551-9; PMID:16867217; http://dx.doi.org/10.1593/neo.06148
15. Di Cintio A, Di Gennaro E, Budillon A. Restoring p53 function in cancer: novel therapeutic approaches for applying the brakes to tumorigenesis. Recent Pat Anticancer Drug Discov 2010; 5:1-13; PMID:19663772; http://dx.doi.org/10. 2174/157489210789702172
16. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, Pramanik A, Selivanova G. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004; 10:1321-8; PMID:15558054; http://dx.doi.org/10.1038/nm1146
17. Zhao CY, Grinkevich VV, Nikulenkov F, Bao W, Selivanova G. Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA. Cell Cycle 2010; 9:1847-55; PMID:20436301; http://dx.doi.org/10.4161/cc.9.9.11545
18. Girardini JE, Del Sal G. Improving pharmacological rescue of p53 function: RITA targets mutant p53. Cell Cycle 2010; 9:2062; PMID:20559030; http://dx.doi.org/10.4161/cc.9.11.11859
19. Enge M, Bao W, Hedström E, Jackson SP, Moumen A, Selivanova G. MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell 2009; 15:171-83; PMID:19249676; http://dx.doi.org/10.1016/j.ccr.2009.01.019
20. Roh JL, Ko JH, Moon SJ, Ryu CH, Choi JY, Koch WM. The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer. Cancer Lett 2012; 325:35-41; PMID:22634494; http://dx.doi.org/10.1016/j.canlet.2012.05.020
21. Henze J, Mühlenberg T, Simon S, Grabellus F, Rubin B, Taeger G, Schuler M, Treckmann J, Debiec-Rychter M, Taguchi T, et al. p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors. PLoS One 2012; 7:e37776; PMID:22662219; http://dx.doi.org/10.1371/journal.pone.0037776
22. Musti M, Kettunen E, Dragonieri S, Lindholm P, Cavone D, Serio G, Knuutila S. Cytogenetic and molecular genetic changes in malignant mesothelioma. Cancer Genet Cytogenet 2006; 170:9-15; PMID:16965949; http://dx.doi.org/10. 1016/j.cancergencyto.2006.04.011
23. Romagnoli S, Fasoli E, Vaira V, Falleni M, Pellegrini C, Catania A, Roncalli M, Marchetti A, Santambrogio L, Coggi G, et al. Identification of potential therapeutic targets in malignant mesothelioma using cell cycle gene expression analysis. Am J Pathol 2009; 174:762-70; PMID:19218339; http://dx.doi.org/10.2353/ajpath.2009.080721
24. Lunn RM, Zhang YJ, Wang LY, Chen CJ, Lee PH, Lee CS, Tsai WY, Santella RM. p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan. Cancer Res 1997; 57:3471-7; PMID:9270015
25. Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer 2009; 9:95-107; PMID:19165225; http://dx.doi.org/ 10.1038/nrc2584
26. Moran DM, Maki CG. Nutlin-3a induces cytoskeletal rearrangement and inhibits the migration and invasion capacity of p53 wild-type cancer cells. Mol Cancer Ther 2010; 9:895-905; PMID:20371712; http://dx.doi.org/10.1158/1535-7163. MCT-09-1220
27. Ahmed A, Yang J, Maya-Mendoza A, Jackson DA, Ashcroft M. Pharmacological activation of a novel p53-dependent S-phase checkpoint involving CHK-1. Cell Death Dis 2011; 2:e160; PMID:21593792; http://dx.doi.org/10.1038/cddis.2011.42
28. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009; 9:400-14; PMID:19440234; http://dx.doi.org/10. 1038/nrc2657
29. Rinaldo C, Prodosmo A, Siepi F, Moncada A, Sacchi A, Selivanova G, Soddu S. HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA. Cancer Res 2009; 69:6241-8; PMID:19638586; http://dx.doi.org/10.1158/0008-5472.CAN-09-0337
30. Saha MN, Jiang H, Mukai A, Chang H. RITA inhibits multiple myeloma cell growth through induction of p53-mediated caspase-dependent apoptosis and synergistically enhances nutlin-induced cytotoxic responses. Mol Cancer Ther 2010; 9:3041-51; PMID:21062913; http://dx.doi.org/10.1158/1535-7163.MCT-10-0471
31. Koster R, Timmer-Bosscha H, Bischoff R, Gietema JA, de Jong S. Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway. Cell Death Dis 2011; 2:e148; PMID:21509038; http://dx.doi.org/10.1038/cddis. 2011.33
32. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV, Gudkov AV. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999; 285:1733-7; PMID:10481009; http://dx.doi.org/10.1126/science.285.5434.1733
33. Strom E, Sathe S, Komarov PG, Chernova OB, Pavlovska I, Shyshynova I, Bosykh DA, Burdelya LG, Macklis RM, Skaliter R, et al. Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol 2006; 2:474-9; PMID:16862141; http://dx.doi.org/10.1038/nchembio809
34. Di Conza G, Buttarelli M, Monti O, Pellegrino M, Mancini F, Pontecorvi A, Scotlandi K, Moretti F. IGF-1R/MDM2 relationship confers enhanced sensitivity to RITA in Ewing sarcoma cells. Mol Cancer Ther 2012; 11:1247-56; PMID:22461661; http://dx.doi.org/10.1158/1535-7163.MCT-11-0913
35. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1992; 256:827-30; PMID:1589764; http://dx.doi.org/10.1126/science.1589764
36. Mazzoni E, Corallini A, Cristaudo A, Taronna A, Tassi G, Manfrini M, Comar M, Bovenzi M, Guaschino R, Vaniglia F, et al. High prevalence of serum antibodies reacting with simian virus 40 capsid protein mimotopes in patients affected by malignant pleural mesothelioma. Proc Natl Acad Sci U S A 2012; 109:18066-71; PMID:23071320; http://dx.doi.org/10.1073/pnas.1213238109
37. Carbone M, Rizzo P, Grimley PM, Procopio A, Mew DJ, Shridhar V, de Bartolomeis A, Esposito V, Giuliano MT, Steinberg SM, et al. Simian virus-40 large-T antigen binds p53 in human mesotheliomas. Nat Med 1997; 3:908-12; PMID:9256284; http://dx.doi.org/10.1038/nm0897-908
38. Soini Y, Chia SC, Bennett WP, Groopman JD, Wang JS, DeBenedetti VM, Cawley H, Welsh JA, Hansen C, Bergasa NV, et al. An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. Carcinogenesis 1996; 17:1007-12; PMID:8640905; http://dx.doi.org/10.1093/carcin/17.5.1007
39. Aung W, Hasegawa S, Furukawa T, Saga T. Potential role of ferritin heavy chain in oxidative stress and apoptosis in human mesothelial and mesothelioma cells: implications for asbestos-induced oncogenesis. Carcinogenesis 2007; 28:2047-52; PMID:17434931; http://dx.doi.org/10.1093/carcin/bgm090
40. Villanova F, Procopio A, Rippo MR. Malignant mesothelioma resistance to apoptosis: recent discoveries and their implication for effective therapeutic strategies. Curr Med Chem 2008; 15:631-41; PMID:18336278; http://dx.doi.org/10. 2174/092986708783885273
41. Xia C, Xu Z, Yuan X, Uematsu K, You L, Li K, Li L, McCormick F, Jablons DM. Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol Cancer Ther 2002; 1:687-94; PMID:12479365
42. Falleni M, Pellegrini C, Marchetti A, Roncalli M, Nosotti M, Palleschi A, Santambrogio L, Coggi G, Bosari S. Quantitative evaluation of the apoptosis regulating genes Survivin, Bcl-2 and Bax in inflammatory and malignant pleural lesions. Lung Cancer 2005; 48:211-6; PMID:15829320; http://dx.doi.org/10.1016/j. lungcan.2004.10.003
43. Zaffaroni N, Costa A, Pennati M, De Marco C, Affini E, Madeo M, Erdas R, Cabras A, Kusamura S, Baratti D, et al. Survivin is highly expressed and promotes cell survival in malignant peritoneal mesothelioma. Cell Oncol 2007; 29:453-66; PMID:18032822
44. Gordon GJ, Mani M, Mukhopadhyay L, Dong L, Edenfield HR, Glickman JN, Yeap BY, Sugarbaker DJ, Bueno R. Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma. J Pathol 2007; 211:447-54; PMID:17253596; http://dx.doi.org/10.1002/path.2121
45. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002; 277:3247-57; PMID:11714700; http://dx.doi.org/10.1074/jbc.M106643200
46. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002; 21:2613-22; PMID:11965534; http://dx.doi.org/10.1038/sj.onc.1205353
47. Kracikova M, Akiri G, George A, Sachidanandam R, Aaronson SA. A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis. Cell Death Differ 2013; 20:576-88; PMID:23306555; http://dx.doi.org/10.1038/cdd. 2012.155
48. Gordon GJ, Appasani K, Parcells JP, Mukhopadhyay NK, Jaklitsch MT, Richards WG, Sugarbaker DJ, Bueno R. Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma. Carcinogenesis 2002; 23:1017-24; PMID:12082024; http://dx.doi.org/10.1093/carcin/23.6.1017
49. Lazzarini R, Moretti S, Orecchia S, Betta PG, Procopio A, Catalano A. Enhanced antitumor therapy by inhibition of p21waf1 in human malignant mesothelioma. Clin Cancer Res 2008; 14:5099-107; PMID:18698027; http://dx.doi.org/10.1158/1078-0432.CCR-08-0255
50. Sandor V, Senderowicz A, Mertins S, Sackett D, Sausville E, Blagosklonny MV, Bates SE. P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer 2000; 83:817-25; PMID:10952788; http://dx.doi.org/10.1054/bjoc.2000.1327
51. Almenara J, Rosato R, Grant S. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia 2002; 16:1331-43; PMID:12094258; http://dx.doi.org/10.1038/sj.leu.2402535
52. Nguyen DM, Schrump WD, Chen GA, Tsai W, Nguyen P, Trepel JB, Schrump DS. Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clin Cancer Res 2004; 10:1813-25; PMID:15014036; http://dx.doi.org/10.1158/1078-0432.CCR-0901-3
53. Grinkevich VV, Nikulenkov F, Shi Y, Enge M, Bao W, Maljukova A, Gluch A, Kel A, Sangfelt O, Selivanova G. Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis. Cancer Cell 2009; 15:441-53; PMID:19411072; http://dx.doi.org/10.1016/j.ccr.2009.03.021
54. Hedström E, Eriksson S, Zawacka-Pankau J, Arnér ES, Selivanova G. p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA. Cell Cycle 2009; 8:3576-83; PMID:19838062; http://dx.doi.org/10.4161/cc.8.21.9977
55. Nilsonne G, Sun X, Nyström C, Rundlöf AK, Potamitou Fernandes A, Björnstedt M, Dobra K. Selenite induces apoptosis in sarcomatoid malignant mesothelioma cells through oxidative stress. Free Radic Biol Med 2006; 41:874-85; PMID:16934670; http://dx.doi.org/10.1016/j.freeradbiomed.2006.04.031
56. Busacca S, Germano S, De Cecco L, Rinaldi M, Comoglio F, Favero F, Murer B, Mutti L, Pierotti M, Gaudino G. MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. Am J Respir Cell Mol Biol 2010; 42:312-9; PMID:19502386; http://dx.doi.org/10.1165/rcmb.2009-0060OC
57. Indovina P, Giorgi F, Rizzo V, Khadang B, Schenone S, Di Marzo D, Forte IM, Tomei V, Mattioli E, D'Urso V, et al. New pyrazolo[3,4-d]pyrimidine SRC inhibitors induce apoptosis in mesothelioma cell lines through p27 nuclear stabilization. Oncogene 2012; 31:929-38; PMID:21785466; http://dx.doi.org/10. 1038/onc.2011.286
58. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75:817-25; PMID:8242752; http://dx.doi.org/10.1016/0092- 8674(93)90500-P
59. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55; PMID:6382953; http://dx.doi.org/10.1016/0065-2571(84)90007-4
60. Euhus DM, Hudd C, LaRegina MC, Johnson FE. Tumor measurement in the nude mouse. J Surg Oncol 1986; 31:229-34; PMID:3724177; http://dx.doi.org/10.1002/ jso.2930310402
61. Indovina P, Marcelli E, Di Marzo D, Casini N, Forte IM, Giorgi F, Alfano L, Pentimalli F, Giordano A. Abrogating G 2/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma. Cancer Biol Ther 2013; 15; PMID:24365782